NFATC2IP and cardiac hypertrophy: Further, we found that Nfatc2ip activates β‐Mhc transcription by targeting the core‐promoter of β‐Mhc, and miR‐31‐5p inhibits Nfatc2ip‐β‐Mhc signalling to prevent cardiac hypertrophy.